Guerbet: 2020 Half-year results
2020 half-year results
Visit link:
Guerbet: 2020 Half-year results
Author Archives: admin
Saniona announces outcome of warrant exercise
PRESS RELEASE
Read the original here:
Saniona announces outcome of warrant exercise
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that positive results from the two pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the Journal of the American Medical Association (JAMA) Dermatology.
See more here:
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
electroCore to Participate in the JMP Securities MedTech Bio Summit
BASKING RIDGE, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will participate in a fireside chat at the JMP Securities MedTech Bio Summit, which is being held virtually October 1-2, 2020.
Excerpt from:
electroCore to Participate in the JMP Securities MedTech Bio Summit
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone…
COPENHAGEN, Denmark, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it has filed a Clinical Trial Notification (CTN) with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to initiate the company’s phase 3 riGHt Trial of TransCon™ hGH (lonapegsomatropin), a long-acting prodrug of somatropin (hGH), for the treatment for pediatric growth hormone deficiency (GHD).
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020 Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020
View original post here:
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Parexel Announces Solution for EU Clinical Trials Information System Regulation
Resource hub streamlines and simplifies application process for clinical trials within EU Resource hub streamlines and simplifies application process for clinical trials within EU
Visit link:
Parexel Announces Solution for EU Clinical Trials Information System Regulation
One World Pharma Releases Investor Presentation
Television Legend Montel Williams Joins Isiah Thomas During Live Q&A
Read the rest here:
One World Pharma Releases Investor Presentation
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.
View post:
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science
Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases
View original post here:
Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science